Michael Pourdehnad, MD

Hematologist
Oncologist

Dr. Michael Pourdehnad is a hematologist-oncologist who specializes in cancers that originate in blood-forming tissues or immune system cells. He also has expertise in noncancerous disorders of the blood.

Pourdehnad is a physician-scientist, a medical doctor who devotes much time to research. In addition to treating patients, he is dedicated to developing novel therapies for cancer patients with especially challenging cases. In this capacity, he also works with the biotechnology company Celgene to translate research discoveries into new treatments for blood cancers.

After earning his medical degree from Chicago Medical School at Rosalind Franklin University School of Medicine and Science, Pourdehnad completed a residency in internal medicine at Icahn School of Medicine at Mount Sinai, where he served as chief resident. He then completed a fellowship in adult hematologic malignancies and blood and marrow transplantation at UCSF.

Clinics

Hematology and Blood and Marrow Transplant
400 Parnassus Ave., Fourth Floor
San Francisco, CA 94143
Existing Patients: (415) 353-2421
New Patients: (415) 353-2051
Fax: (415) 353-2467

Hours: Monday to Friday, 8 a.m. - 5 p.m

Board Certification

Internal Medicine, American Board of Internal Medicine

More about Michael Pourdehnad

Education

Chicago Medical School at Rosalind Franklin University School of Medicine and Science 2005

Residencies

Icahn School of Medicine at Mount Sinai, Internal Medicine 2008

Fellowships

UCSF, Adult Hematologic Malignancies and Blood and Marrow Transplantation 2012

Selected Research and Publications

  1. Hagner PR, Man HW, Fontanillo C, Wang M, Couto S, Breider M, Bjorklund C, Havens CG, Lu G, Rychak E, Raymon H, Narla RK, Barnes L, Khambatta G, Chiu H, Kosek J, Kang J, Amantangelo MD, Waldman M, Lopez-Girona A, Cai T, Pourdehnad M, Trotter M, Daniel TO, Schafer PH, Klippel A, Thakurta A, Chopra R, Gandhi AK. CC-122, a pleiotropic pathway modifier, mimics an interferon response and has antitumor activity in DLBCL. Blood. 2015 Aug 06; 126(6):779-89.
  2. Pourdehnad M, Truitt ML, Siddiqi IN, Ducker GS, Shokat KM, Ruggero D. Myc and mTOR converge on a common node in protein synthesis control that confers synthetic lethality in Myc-driven cancers. Proc Natl Acad Sci U S A. 2013 Jul 16; 110(29):11988-93.
  3. Cunningham JT, Pourdehnad M, Stumpf CR, Ruggero D. Investigating Myc-dependent translational regulation in normal and cancer cells. Methods Mol Biol. 2013; 1012:201-12.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.